Key Takeaways
1. Imfinzi (durvalumab) is AstraZeneca's wholly owned anti-PD-L1 immune checkpoint inhibitor, approved across the UK, EU and US in a broadening set of cancers.
2. The label spans unresectable and resectable non-small cell lung cancer, small cell lung cancer, biliary tract, hepatocellular, endometrial, bladder and resectable gastric/gastro-oesophageal junction cancers, often in combination regimens.
3. Indications must be read separately by jurisdiction: for example, the US Stage III NSCLC label has no PD-L1 threshold while the UK and EU require PD-L1 expression on at least 1% of tumour cells.
4. Imfinzi is one of AstraZeneca's principal oncology medicines; its product-level revenue is disclosed in the company's own financial results rather than estimated here.
5. Principal risks include intense checkpoint-inhibitor competition, trial and regulatory risk, HTA/reimbursement divergence, immune-mediated side effects and eventual loss of exclusivity.
Introduction
The central question for investors is straightforward: why does AstraZeneca plc (LSE:AZN) keep pushing its immunotherapy Imfinzi into new cancers, and what does that mean for the company? Imfinzi, whose active substance is durvalumab, is a wholly owned anti-PD-L1 monoclonal antibody and one of AstraZeneca's principal oncology medicines.
As of the verification date, it is fully approved across the UK, EU and US in a broad and expanding oncology label covering lung, gastrointestinal, genitourinary and gynaecological tumours. The strategy is to combine durvalumab with chemotherapy, radiotherapy or AstraZeneca's own antibody tremelimumab, and to move treatment earlier into the disease course toward curative-intent, resectable settings.
This article examines what Imfinzi is, how it works, which indications are approved in each jurisdiction, its portfolio importance, competition and risks. It does not estimate revenue and does not offer investment or medical advice.
What is Imfinzi?
Imfinzi is the brand name for durvalumab, a biologic medicine given by intravenous infusion. It belongs to the immuno-oncology class known as immune checkpoint inhibitors and is used to treat several types of cancer according to its approved product information.
Imfinzi is a wholly owned AstraZeneca asset. There is no ViiV or Alexion-style joint venture or third-party licensing structure for the core product. The UK marketing authorisation is held by AstraZeneca UK Limited, while the EU centralised marketing authorisation is held by AstraZeneca AB in Sweden; both are subsidiaries of the ultimate parent, AstraZeneca plc (LSE:AZN).
It is worth noting what a regulatory substance listing does and does not establish. The presence of product files in a regulator's substance index evidences only that regulatory documentation exists. It is not, by itself, proof of a new approval, a change of ownership, a product launch or commercial success. Approvals and indications are confirmed through the summary of product characteristics, the EMA product information and FDA labelling.
How does durvalumab work?
According to the approved product information, durvalumab is a human immunoglobulin G1 kappa (IgG1k) monoclonal antibody. It blocks the interaction of programmed cell death ligand-1 (PD-L1) with the PD-1 and CD80 (B7.1) receptors.
Some tumours use PD-L1 to switch off immune cells that would otherwise attack them. By blocking that signal, durvalumab releases the inhibition of anti-tumour immune responses, allowing the immune system to recognise and target cancer cells. This is why it is described as an anti-PD-L1 immune checkpoint inhibitor.
The antibody's Fc domain is engineered to reduce antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. In certain regimens durvalumab is paired with tremelimumab (Imjudo), AstraZeneca's own anti-CTLA-4 antibody, to engage a second, complementary immune checkpoint pathway.
Which cancer indications are approved?
Imfinzi carries a wide oncology label, but indications must be verified separately by jurisdiction and not merged. In the UK, Imfinzi is approved in unresectable, locally advanced NSCLC (PACIFIC), resectable NSCLC (AEGEAN), limited-stage SCLC (ADRIATIC), extensive-stage SCLC (CASPIAN), biliary tract cancer (TOPAZ-1), hepatocellular carcinoma (HIMALAYA), endometrial cancer (DUO-E), muscle-invasive bladder cancer (NIAGARA) and resectable gastric/gastro-oesophageal junction cancer (MATTERHORN).
The EU label is broadly similar and additionally includes first-line metastatic NSCLC in combination with tremelimumab and chemotherapy (POSEIDON). The EU gastric/GEJ approval (MATTERHORN) was announced on 16 March 2026, and the resectable NSCLC approval (AEGEAN) on 4 April 2025.
Several jurisdictional differences matter. The US Stage III NSCLC label has no PD-L1 expression requirement, whereas the UK and EU require PD-L1 expression on at least 1% of tumour cells. The US endometrial indication is restricted to mismatch repair deficient (dMMR) disease, while the UK and EU cover both dMMR (maintenance monotherapy) and pMMR (maintenance with olaparib).
The US also carries an additional approval not identified in the UK or EU labels reviewed: durvalumab with Bacillus Calmette-Guerin (BCG) for BCG-naive, high-risk non-muscle invasive bladder cancer (POTOMAC), approved by the FDA on 28 May 2026.
What combination regimens are relevant?
Much of Imfinzi's expansion has come through combination and perioperative regimens rather than monotherapy alone. In resectable NSCLC, the AEGEAN regimen pairs durvalumab with platinum-based chemotherapy before surgery, followed by Imfinzi monotherapy afterwards, in tumours without EGFR mutations or ALK rearrangements.
In gastrointestinal cancers, durvalumab is combined with gemcitabine and cisplatin in biliary tract cancer (TOPAZ-1), with etoposide and platinum chemotherapy in extensive-stage SCLC (CASPIAN), and with FLOT chemotherapy in the perioperative gastric/GEJ setting (MATTERHORN). In hepatocellular carcinoma, the HIMALAYA regimen combines durvalumab with tremelimumab.
In gynaecological and genitourinary disease, durvalumab is used with carboplatin and paclitaxel in endometrial cancer (DUO-E), sometimes followed by maintenance with olaparib depending on mismatch repair status, and with gemcitabine and cisplatin in the perioperative bladder cancer regimen (NIAGARA). These combinations reflect a deliberate strategy to move immunotherapy earlier in treatment, including into curative-intent settings.
How important is Imfinzi to AstraZeneca?
Imfinzi is one of AstraZeneca's principal oncology medicines and a material contributor to its oncology franchise. Its product-level revenue is separately disclosed within the Oncology therapy area in AstraZeneca plc's annual report and quarterly financial results.
No specific revenue figure, market share or growth percentage is asserted here, because none was retrieved from a primary AstraZeneca financial disclosure during verification. Readers seeking exact figures should take them directly from the relevant AstraZeneca results statement rather than relying on an estimate.
Qualitatively, the investment case rests on breadth and durability. The label continues to broaden across lung, gastrointestinal, genitourinary and gynaecological tumours, and the shift into earlier, resectable and perioperative settings potentially lengthens treatment duration and widens the eligible patient population. Commercial performance will ultimately depend on uptake, competition, pricing and reimbursement.
What is the addressable market and what could drive growth?
The tumour types where Imfinzi is approved are among the more common and serious cancers, including lung, liver, biliary tract, bladder, stomach and endometrial cancers. Qualitatively, this represents a large potential patient population, though the funded, addressable market in any country depends on health-technology assessment and reimbursement decisions rather than the marketing authorisation alone.
Growth drivers may include continued label expansion into new indications, the move into earlier-stage and perioperative treatment, and combination regimens that can extend the duration of therapy. The recent gastric/GEJ and NMIBC approvals illustrate how new indications can open additional patient segments.
Investors may monitor the cadence of regulatory approvals across jurisdictions, the outcome of confirmatory trials, and how quickly newly approved regimens are adopted and funded. These factors, rather than headline population statistics, tend to determine realised commercial performance.
What immunotherapy competition does it face?
Imfinzi operates in a crowded and competitive immuno-oncology market. Direct competitors include Merck's anti-PD-1 antibody pembrolizumab (Keytruda), Roche/Genentech's anti-PD-L1 atezolizumab (Tecentriq) and Bristol Myers Squibb's anti-PD-1 nivolumab (Opdivo).
Additional checkpoint inhibitors include cemiplimab (Libtayo, Regeneron/Sanofi), avelumab (Bavencio, Merck KGaA/Pfizer) and tislelizumab (Tevimbra, BeOne/BeiGene). Competition is particularly intense in overlapping lung and gastrointestinal indications, where several of these agents hold approvals.
This means Imfinzi frequently competes not on class novelty but on specific trial data, regimen design, tolerability and access. Differentiation through earlier-line and perioperative approvals, and through combinations with tremelimumab, is central to how AstraZeneca positions the product.
What risks remain?
Several risks could affect Imfinzi's trajectory. The most immediate is intense competition within the checkpoint-inhibitor class, especially where pembrolizumab, atezolizumab and nivolumab overlap in lung and gastrointestinal indications. Over the medium term, loss of exclusivity and the eventual emergence of biosimilars could pressure the franchise; no durvalumab biosimilar approval was identified during verification.
Clinical trial risk is inherent to label expansion: failure of confirmatory or label-expansion studies could limit growth or, in some cases, trigger withdrawal of accelerated approvals. Regulatory and reimbursement risk is also significant, as divergent HTA outcomes, for example from NICE or the SMC in the UK, may restrict funded use even where a marketing authorisation exists.
As an immunotherapy, durvalumab carries the potential for immune-mediated adverse events such as pneumonitis, colitis, hepatitis and endocrinopathies, requiring ongoing pharmacovigilance and careful patient management per the approved product information. Broader pricing pressure and pharmaceutical policy changes across major markets add further uncertainty.
Finally, jurisdictional label divergence, such as differing PD-L1 thresholds and the dMMR restriction in US endometrial cancer, creates access complexity that clinicians, payers and investors need to track carefully. None of these risks is unique to AstraZeneca, but together they shape the outlook for Imfinzi.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...